Results 41 to 50 of about 58,002 (312)

Synthesis and Structure-Activity Relationships of Pyridoxal-6-arylazo-5'-phosphate and Phosphonate Derivatives as P2 Receptor Antagonists. [PDF]

open access: yes, 1998
Novel analogs of the P2 receptor antagonist pyridoxal-5'-phosphate-6-phenylazo-2',4'-disulfonate (PPADS) were synthesized. Modifications were made through functional group substitution on the sulfophenyl ring and at the phosphate moiety through the ...
Boyer, José L.   +13 more
core   +3 more sources

Comparing the sensitivity of pyridoxal-5-phosphate, homocysteine and neopterin in coronary heart disease

open access: yesPteridines, 2002
Blood serum pyridoxal-5-phosphate, homocysteine and neopterin concentrations have been examined in 30 healthy individuals and 87 patients with coronary heart disease, verified by coronary angiography.
Rudzite Vera   +7 more
doaj   +1 more source

Cloning and Characterization of Pyridoxal Kinase from Geobacillus sp. H6a

open access: yesJournal of Pure and Applied Microbiology, 2022
Pyridoxal kinase encoded by pdxK gene, is the important key enzyme in the salvage pathway of vitamin B6 biosynthesis. The enzyme catalyzes the phosphorylation of the 5′ alcohol groups of free form vitamin B6 into their 5′-phosphate forms that requires ...
Jumnong Pasri   +2 more
doaj   +1 more source

Molecular mechanisms of the non-coenzyme action of thiamin in brain. Biochemical, structural and pathway analysis [PDF]

open access: yes, 2015
Thiamin (vitamin B1) is a pharmacological agent boosting central metabolism through the action of the coenzyme thiamin diphosphate (ThDP). However, positive effects, including improved cognition, of high thiamin doses in neurodegeneration may be ...
Andrey, Vovk   +9 more
core   +1 more source

Crystal structure of L-aspartate aminotransferase from Schizosaccharomyces pombe.

open access: yesPLoS ONE, 2019
L-aspartate aminotransferase is a pyridoxal 5'-phosphate-dependent transaminase that catalyzes reversible transfer of an α-amino group from aspartate to α-ketoglutarate or from glutamate to oxaloacetate.
Soo Yeon Jeong   +2 more
doaj   +1 more source

Structural Basis of the Substrate Specificity and Enzyme Catalysis of a Papaver somniferum Tyrosine Decarboxylase

open access: yesFrontiers in Molecular Biosciences, 2017
Tyrosine decarboxylase (TyDC), a type II pyridoxal 5′-phosphate decarboxylase, catalyzes the decarboxylation of tyrosine. Due to a generally high sequence identity to other aromatic amino acid decarboxylases (AAADs), primary sequence information is not ...
Huai Guan   +12 more
doaj   +1 more source

It takes two to tango: defining an essential second active site in pyridoxal 5'-phosphate synthase. [PDF]

open access: yesPLoS ONE, 2011
The prevalent de novo biosynthetic pathway of vitamin B6 involves only two enzymes (Pdx1 and Pdx2) that form an ornate multisubunit complex functioning as a glutamine amidotransferase.
Cyril Moccand   +2 more
doaj   +1 more source

Two-Photon Excited Fluorescence of NADH-Alcohol Dehydrogenase Complex in a Mixture with Bacterial Enzymes

open access: yesBiomolecules, 2023
Thorough study of composition and fluorescence properties of a commercial reagent of active equine NAD-dependent alcohol dehydrogenase expressed and purified from E. coli has been carried out. Several experimental methods: spectral- and time-resolved two-
Ioanna A. Gorbunova   +6 more
doaj   +1 more source

Rv2607 from Mycobacterium tuberculosis is a pyridoxine 5'-phosphate oxidase with unusual substrate specificity. [PDF]

open access: yesPLoS ONE, 2011
Despite intensive effort, the majority of the annotated Mycobacterium tuberculosis genome consists of genes encoding proteins of unknown or poorly understood function.
Ellene H Mashalidis   +6 more
doaj   +1 more source

Pharmaceutical compounding of orphan active ingredients in Belgium : how community and hospital pharmacists can address the needs of patients with rare diseases [PDF]

open access: yes, 2019
Background: Pharmaceutical compounding of orphan active ingredients can offer cost-effective treatment to patients when no other drug product is available for a rare disease or during periods of drug product shortages.
Boussery, Koen   +7 more
core   +2 more sources

Home - About - Disclaimer - Privacy